– Named Most Innovative Healthcare Company of 2019 for its Nanocell Platform
for Targeted Cyto-Immunotherapy in Cancer Treatment
EnGeneIC Limited , a clinical-stage biopharmaceutical company advancing its proprietary EDV(TM) nanocell platform for targeted cyto-immunotherapy in cancer, was named the most innovative company in the category of healthcare for 2019 by The Australian Financial Review in its 8th annual AFR BOSS Most Innovative Companies list.
AFR BOSS Most Innovative Companies list recognizes the most innovative companies in Australia and New Zealand as judged by the expert panel assembled by The Australian Financial Review and Inventium, a leading innovation consultancy. Awards are issued to companies across 10 industry categories.
Submissions were rated based on a number of criteria, including, the idea behind the innovation; how well that idea addressed the problem it aims to solve; the uniqueness of the solution; and the real-world impact. The rankings also took into consideration whether the company’s culture, entrepreneurial spirit, strategy, resources and talent are capable of sustainable and repeatable innovation.
EnGeneIC was also awarded “Best Health Industries Innovation” and “Best Health Industries Innovation Program.” Accepting the award were Himanshu Brahmbhatt, M.Sc., Ph.D., and Jennifer MacDiarmid, M.Sc., Ph.D., co.-founders and Joint-CEOs of EnGeneIC.
“We are very proud of this award,” they said, “A biotechnology company is its innovation and without invention and out-of-the box thinking, it would be impossible to envisage success in a field such as immuno-oncology.”
“We are a small company, but we have huge ambitions supported by the hard work of a diverse group of people dedicated to finding better treatment options for cancer. It is due to our team’s efforts that we prevailed over larger companies with considerably more resources, which goes to show what a committed group of people can accomplish.”
EnGeneIC targeted nanocell, the EDV(TM) is designed to deliver a toxic payload to a tumor without harming other cells in the body while simultaneously stimulating and anti-tumor immune response. The technology is yielding early success in a pancreatic cancer trial for patients with stage IV cancer who have exhausted all treatment options.
Details about the awards and the list can be found here .
About EnGeneIC and the EDV(TM) Nanocell Technology
EnGeneIC is a clinical stage biopharmaceutical company advancing its proprietary bacterially-derived EDV(TM) nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system’s innate and adaptive anti-tumor response. The novel second-generation EDV(TM) nanocells have shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.
